BR100 Decreased By (-0%)
BR30 Decreased By (-0.12%)
KSE100 No Change (0%)
KSE30 No Change (0%)
BECO 6.03 Increased By ▲ 0.26 (4.51%)
BML 52.75 Decreased By ▼ -0.25 (-0.47%)
BOP 34.25 Increased By ▲ 0.26 (0.76%)
CNERGY 8.16 Increased By ▲ 0.05 (0.62%)
DCL 12.34 Increased By ▲ 0.14 (1.15%)
FCCL 53.89 Increased By ▲ 1.06 (2.01%)
FCSC 5.22 Increased By ▲ 0.15 (2.96%)
FFL 18.03 Increased By ▲ 0.08 (0.45%)
FNEL 1.30 Increased By ▲ 0.01 (0.78%)
HUMNL 11.00 Increased By ▲ 0.12 (1.1%)
KEL 8.11 Increased By ▲ 0.09 (1.12%)
KOSM 5.38 Decreased By ▼ -0.14 (-2.54%)
MLCF 88.05 Increased By ▲ 1.54 (1.78%)
NBP 186.48 Increased By ▲ 1.32 (0.71%)
PACE 10.72 Increased By ▲ 0.14 (1.32%)
PAEL 39.94 Increased By ▲ 0.52 (1.32%)
PIAHCLA 26.17 Decreased By ▼ -0.05 (-0.19%)
PIBTL 17.32 Increased By ▲ 0.65 (3.9%)
PPL 232.78 Increased By ▲ 4.60 (2.02%)
PRL 34.95 Increased By ▲ 0.27 (0.78%)
PTC 67.56 Increased By ▲ 2.23 (3.41%)
SEARL 90.93 Increased By ▲ 0.80 (0.89%)
SSGC 27.17 Increased By ▲ 0.57 (2.14%)
TELE 8.57 Increased By ▲ 0.29 (3.5%)
THCCL 60.13 Increased By ▲ 1.63 (2.79%)
TPLP 8.76 Increased By ▲ 0.54 (6.57%)
TREET 24.54 Increased By ▲ 0.01 (0.04%)
TRG 71.75 Increased By ▲ 2.04 (2.93%)
WAVES 9.98 Increased By ▲ 0.04 (0.4%)
WTL 1.26 Decreased By ▼ -0.02 (-1.56%)
World

Moderna files for US authorization to use its COVID-19 vaccine in teens

  • Moderna's vaccine is already being used in the United States, the European Union and Canada for anyone over 18.
Published June 10, 2021 Updated June 10, 2021 07:01pm
By

Moderna Inc said on Thursday it has filed for US authorization to use its COVID-19 vaccine in adolescents aged 12 to 18, the latest company to seek approval to help expand the inoculation drive in the country.

Moderna's vaccine is already being used in the United States, the European Union and Canada for anyone over 18. The drugmaker has already submitted applications to the European and Canadian health regulators seeking authorization for the vaccine's use in adolescents.

Moderna's two-shot vaccine last month was shown to be effective in adolescents aged 12-17 and showed no new or major safety problems in a clinical trial which evaluated the vaccine in 3,732 teenagers.

Vaccinating children has been considered key to achieving "herd immunity" and the US has already authorized Pfizer and German partner BioNTech SE's COVID-19 vaccine for use in children as young as 12.

Comments

Comments are closed for this article.